Andrew Tsourkas
Overview
Explore the profile of Andrew Tsourkas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
140
Citations
3418
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jang B, Amirshaghaghi A, Choi J, Miller J, Issadore D, Busch T, et al.
ACS Nano
. 2025 Jan;
19(1):1794-1808.
PMID: 39749910
Nanoparticles have gained attention as drug delivery vehicles for cancer treatment, but often struggle with poor tumor accumulation and penetration. Single external magnets can enhance magnetic nanoparticle delivery but are...
2.
Kim B, Subraveti S, Liu J, Nayagam S, Merghoub S, Caggiano N, et al.
ACS Appl Bio Mater
. 2024 Oct;
7(11):7595-7607.
PMID: 39480746
Despite the recent advances and clinical demonstration of lipid nanoparticles (LNPs) for therapeutic and prophylactic applications, the extrahepatic delivery of nucleic acids remains a significant challenge in the field. This...
3.
Habibollahi P, Gurevich A, Hui J, Weinfurtner K, McClung G, Adler J, et al.
Mol Cancer Ther
. 2024 Sep;
23(12):1815-1826.
PMID: 39312187
Glypican-3 (GPC3) is a proteoglycan with high sensitivity and specificity for hepatocellular carcinoma (HCC). We describe the integrated development and validation of a GPC3-targeting optical imaging probe and T cell-redirecting...
4.
Chan A, Haley R, Najar M, Gonzalez-Martinez D, Bugaj L, Burslem G, et al.
Nat Commun
. 2024 Jul;
15(1):5808.
PMID: 38987546
Recently, targeted degradation has emerged as a powerful therapeutic modality. Relying on "event-driven" pharmacology, proteolysis targeting chimeras (PROTACs) can degrade targets and are superior to conventional inhibitors against undruggable proteins....
5.
Omo-Lamai S, Wang Y, Patel M, Essien E, Shen M, Majumdar A, et al.
bioRxiv
. 2024 Apr;
PMID: 38659905
Lipid nanoparticles (LNPs) have emerged as the dominant platform for RNA delivery, based on their success in the COVID-19 vaccines and late-stage clinical studies in other indications. However, we and...
6.
Park J, Kadam P, Atiyas Y, Chhay B, Tsourkas A, Eberwine J, et al.
Angew Chem Int Ed Engl
. 2024 Mar;
63(18):e202401544.
PMID: 38470412
There is growing interest in understanding the biological implications of single cell heterogeneity and heteroplasmy of mitochondrial DNA (mtDNA), but current methodologies for single-cell mtDNA analysis limit the scale of...
7.
Park J, Kadam P, Atiyas Y, Chhay B, Tsourkas A, Eberwine J, et al.
bioRxiv
. 2024 Feb;
PMID: 38352577
There is growing interest in understanding the biological implications of single cell heterogeneity and intracellular heteroplasmy of mtDNA, but current methodologies for single-cell mtDNA analysis limit the scale of analysis...
8.
Chan A, Tsourkas A
BME Front
. 2024 Jan;
5:0035.
PMID: 38282957
Protein biologics are powerful therapeutic agents with diverse inhibitory and enzymatic functions. However, their clinical use has been limited to extracellular applications due to their inability to cross plasma membranes....
9.
Rao M, Murali S, Amores D, Yu F, Tsourkas A
Bioconjug Chem
. 2024 Jan;
35(1):115-124.
PMID: 38173338
Antibody-drug conjugates (ADCs) make up a growing class of targeted therapeutics with important applications in cancer treatment. ADCs are highly modular in nature and thus can be engineered to target...
10.
Tian Y, Carrillo-Malani N, Feng K, Miller J, Busch T, Sundaram K, et al.
Nanotheranostics
. 2024 Jan;
8(1):100-111.
PMID: 38164502
Phthalocyanine (PC) and naphthalocyanine (NC) dyes have long garnered interest as theranostic agents for optical imaging and phototherapy due to their near-infrared absorbance, photostability, imaging contrast, and proven safety in...